Mutational spectrum and prognosis in Chinese patients with prefibrotic primary myelofibrosis

Prefibrotic primary myelofibrosis (Pre‐PMF) has been classified as a separate entity of myeloproliferative neoplasms (MPNs). Pre‐PMF is clinically heterogeneous but a specific prognostic model is lacking. Gene mutations have emerged as useful tools for stratification of myelofibrosis patients. Howev...

Full description

Saved in:
Bibliographic Details
Published in:EJHaem 2022-02, Vol.3 (1), p.184-190
Main Authors: Cheng, Chi‐Keung, Lai, Jennifer W. Y., Yung, Yuk‐Lin, Chan, Hoi‐Yun, Wong, Raymond S. M., Chan, Natalie P. H., Cheung, Joyce S., Luo, Xi, Pitts, Herbert‐Augustus, Ng, Margaret H. L.
Format: Article
Language:English
Subjects:
Bone marrow
Cytogenetics
Genes
Hemoglobin
Medical prognosis
Mutation
Myelofibrosis
myeloproliferative neoplasms
Patients
prefibrotic primary myelofibrosis
prognostic factors
RUNX1
Short Report
Short Reports
TP53
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prefibrotic primary myelofibrosis (Pre‐PMF) has been classified as a separate entity of myeloproliferative neoplasms (MPNs). Pre‐PMF is clinically heterogeneous but a specific prognostic model is lacking. Gene mutations have emerged as useful tools for stratification of myelofibrosis patients. However, there have been limited studies comprehensively investigating the mutational spectrum and its clinicopathological significance in pre‐PMF subjects. In this study, we addressed these issues by profiling the mutation status of 141 genes in 172 Chinese MPN patients including 72 pre‐PMF cases. Our findings corroborated the clinical/molecular distinctiveness of pre‐PMF and suggested a refined risk classification strategy for this entity.
ISSN:2688-6146
2688-6146
DOI:10.1002/jha2.361